Literature DB >> 17327369

Endotoxin attenuates growth hormone-induced hepatic insulin-like growth factor I expression by inhibiting JAK2/STAT5 signal transduction and STAT5b DNA binding.

Yu Chen1, Difei Sun, Vidya M R Krishnamurthy, Ralph Rabkin.   

Abstract

Gram-negative sepsis with release of endotoxin is a frequent cause of cachexia that develops partly because of resistance to growth hormone (GH) with reduced insulin-like growth factor-I (IGF-I) expression. We set out to more fully characterize the mechanisms for the resistance and to determine whether in addition to a defect in the janus kinase 2 (JAK2)-signal transducer and activator of transcription (STAT) 5b pathway, required for GH-induced IGF-I expression, there might also be a more distal defect. Conscious rats were given endotoxin and studied 4 h later. In liver of these animals, GH-induced JAK2 and STAT5 phosphorylation was impaired and appeared to be caused, at least in part, by a marked increase in hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression accompanied by elevated levels of inhibitors of GH signaling, namely cytokine-inducible suppressors of cytokine signaling-1 and -3 and cytokine-inducible SH2 protein (CIS). Nuclear phosphorylated STAT5b levels were significantly depressed to 61% of the control values and represent a potential cause of the reduced GH-induced IGF-I expression. In addition, binding of phosphorylated STAT5b to DNA was reduced to an even greater extent and averaged 17% of the normal control value. This provides a further explanation for the impaired IGF-I gene transcription. Interestingly, when endotoxin-treated rats were treated with GH, there was a marked increase in proinflammatory cytokine gene expression in the liver. If such a response were to occur in humans, this might provide a partial explanation for the adverse effect of GH treatment reported in critically ill patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327369     DOI: 10.1152/ajpendo.00581.2006

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  19 in total

1.  Plasma proteomic profiles of bovine growth hormone transgenic mice as they age.

Authors:  Juan Ding; Darlene E Berryman; John J Kopchick
Journal:  Transgenic Res       Date:  2011-03-02       Impact factor: 2.788

Review 2.  Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.

Authors:  Susan L Samson
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 3.  Hyperglycemia in critical illness: a review.

Authors:  David Brealey; Mervyn Singer
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

4.  Hepatic growth hormone resistance after acute injury.

Authors:  Ryan M Corrick; Li Li; Stuart J Frank; Joseph L Messina
Journal:  Endocrinology       Date:  2013-02-15       Impact factor: 4.736

5.  Endotoxin-induced growth hormone resistance in skeletal muscle.

Authors:  Yu Chen; Sumita Sood; Vidya M R Krishnamurthy; Peter Rotwein; Ralph Rabkin
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

6.  Induction of suppressors of cytokine signaling by the trichothecene deoxynivalenol in the mouse.

Authors:  Chidozie J Amuzie; Junko Shinozuka; James J Pestka
Journal:  Toxicol Sci       Date:  2009-07-22       Impact factor: 4.849

7.  Distinct mechanisms of induction of hepatic growth hormone resistance by endogenous IL-6, TNF-α, and IL-1β.

Authors:  Yueshui Zhao; Xiaoqiu Xiao; Stuart J Frank; Herbert Y Lin; Yin Xia
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-06-03       Impact factor: 4.310

Review 8.  Genomic dissection of the cytokine-controlled STAT5 signaling network in liver.

Authors:  Atsushi Hosui; Lothar Hennighausen
Journal:  Physiol Genomics       Date:  2008-05-06       Impact factor: 3.107

9.  Nuclear factor-kappaB mediates the inhibitory effects of tumor necrosis factor-alpha on growth hormone-inducible gene expression in liver.

Authors:  Mark D Buzzelli; Murali Nagarajan; John F Radtka; Margaret L Shumate; Maithili Navaratnarajah; Charles H Lang; Robert N Cooney
Journal:  Endocrinology       Date:  2008-08-21       Impact factor: 4.736

10.  Low-dose growth hormone is cardioprotective in uremia.

Authors:  Ralph Rabkin; Ibrahim Awwad; Yu Chen; Euan A Ashley; Difei Sun; Sumita Sood; William Clusin; Paul Heidenreich; Grzegorz Piecha; Marie-Luise Gross
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.